On Mar. 12, 2020, INOVIO Pharma announced t has received a new $5 million grant from the Bill & Melinda Gates Foundation to accelerate the testing and scale up of CELLECTRAﾮ 3PSP proprietary smart device for the intradermal delivery of INO-4800, a DNA vaccine for COVID-19.

INO-4800 is in preclinical studies and is planned to advance into Phase 1 clinical trials in the U.S. in April with up to $9 million funding from CEPI. INOVIO plans to accelerate the testing and scale up of the CELLECTRA 3PSP devices to support large scale manufacturing of INO-4800 doses by the end of 2020.